Benzinga | Dec 20, 2021 08:37AM EST

SCYNEXIS Says BREXAFEMME Added To Major National Formulary, Providing Access For Millions More Commercially Insured Patients

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant fungal infections, today announced that BREXAFEMME(r) (ibrexafungerp tablets) has been added to a major national formulary, bringing total coverage for this innovative product to more than 45% of commercially insured patients in the U.S., according to the MMIT database, commonly used to track insurance coverage.

"We are extremely pleased to achieve such a significant level of reimbursement coverage, representing nearly half of commercially insured patients, so early in the launch of BREXAFEMME," said Christine Coyne, Chief Commercial Officer of SCYNEXIS. "This formulary coverage allows appropriate patients to more easily access BREXAFEMME and reinforces recognition by payers of the unmet need that BREXAFEMME is filling for patients with VVC."

BREXAFEMME is a novel first-in-class fungicidal triterpenoid antifungal, designed to kill the yeast causing the infection, including azole-resistant strains. It was approved by the U.S. Food and Drug Administration (FDA) in June 2021 as a treatment for vulvovaginal candidiasis (VVC), commonly referred to as vaginal yeast infection. The one-day oral medication represents the first new antifungal class approved by the FDA in more than 20 years.1